(Q39168624)

English

Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells

scientific article published on 3 June 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

multiple myeloma

1 reference

based on heuristic

inferred from title

Hermann Einsele

4

object named as

Hermann Einsele

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

author name string

Isabel Jungkunz-Stier

1

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Michael Zekl

2

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Thorsten Stühmer

3

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Ruth Seggewiss-Bernhardt

5

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

publication date

3 June 2013

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

55

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

168-176

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Drug-mediated and cellular immunotherapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

The role of natural killer cells in immunity against multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Integration of activating and inhibitory receptor signaling by regulated phosphorylation of Vav1 in immune cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Dasatinib in relapsed or plateau-phase multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Lenalidomide enhances anti-myeloma cellular immunity

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Profound inhibition of antigen-specific T-cell effector functions by dasatinib

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Death receptor-induced signaling pathways are differentially regulated by gamma interferon upstream of caspase 8 processing

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Role of the production of natural killer cell stimulatory factor (NKSF/IL-12) in the ability of B cell lines to stimulate T and NK cell proliferation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Activation of NK cell cytotoxicity

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Human natural killer cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Expression and function of CD95 (FAS/APO-1) in leukaemia-lymphoma tumour lines

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Following TRAIL's path in the immune system

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.794270

21 January 2018

Identifiers

10.3109/10428194.2013.794270

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39168624&oldid=1811585380"